Randomized phase II study of nab-Paclitaxel (nab-PTX) plus Carboplatin(CBDCA) followed by maintenance nab-PTX or TS-1 plus CBDCA followed by maintenance TS-1 as first-line treatment in patients with stage IIIB/IV squamous cell carcinoma of the lung. - Randomized phase II study of nab-PTX plus CBDCA followed by maintenance nab-PTX or TS-1 plus CBDCA followed by maintenance TS-1.

Internationanl University of Health and Welfare, Respiratory Disease center0 sites58 target enrollmentFebruary 1, 2014

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: squamous cell carcinoma of the lung
Sponsor: Internationanl University of Health and Welfare, Respiratory Disease center
Enrollment: 58
Status: Completed
Last Updated: 2 years ago

No summary available.

Registry

who.int

Start Date

February 1, 2014

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Internationanl University of Health and Welfare, Respiratory Disease center

•1\.History of hypersensitivity to drugs or albumin. 2\.Severe infection 3\.Significant comorbid disease (paresis of intestine, ileus, GI bleeding, uncontrolled angina pectoris, cardiac disease, etc) 4\.Massive pleural and cardiac effusion and ascites required for tube drainage. 5\.Cases of administration in the flucytosine. 6\.Patients with superior vena cava syndrome. 7\.Active synchronous malignant neoplasm. 8\.Interstitial pneumonia or pulmonary fibrosis detectable on Chest X ray. 9\.Brain metastases patients in need of treatment, such as an anti\-seizure medication and steroids or have symptoms. 10\.Cases of post\-radiation to the primary tumor. 11\.Cases of palliative bone or brain irradiation within two weeks of proposed entry to this study. 12\.Uncontrolled psychiatric disease. 13\.Pregnancy, breast feeding and suspected pregnancy. 14\.Other conditions not suitable for this study.